MSK Commercialization Ecosystem
As a global leader in oncology innovation, Memorial Sloan Kettering Cancer Center (MSK) has long been committed to accelerating and scaling the translation of scientific discoveries into inventions that will benefit cancer patients worldwide.
One important way that this happens is through the MSK Commercialization Ecosystem, an evolving and integrated set of funds, infrastructure, and incentives that are holistically designed to accelerate and scale innovation partnering, licensing, investing, and collaboration opportunities.
Partnering opportunities across a broad array of new technologies and ready-to-use products in MSK’s life sciences, digital health, and related healthcare portfolios
Nurturing and encouraging a culture of entrepreneurship and innovation across MSK to spur startup creation and investment opportunities for our valued industry partners.
Commercialization programs and accelerators which connect industry partners to MSK expertise and resources in order to empower cutting-edge projects with oncology-focused goals.
With an exceptional record of innovation with lasting impact, we look forward to partnering with corporations, investors, and other academic-research organizations on cutting-edge initiatives aimed at improving the diagnosis, early detection, treatment, and care of cancer patients around the world.
Expert professionals and teams throughout our institution are involved in innovative endeavors aimed at improving the diagnosis, treatment, and delivery of care for patients with cancer worldwide.
Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.
Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024.
The U.S. Food and Drug Administration (FDA) qualified MSK’s WOUND-Q™ questionnaire as a Medical Device Development Tool (MDDT) in November 2024. WOUND-Q is the latest of only 18 MDDTs that have earned the qualification since the MDDT program began in 2017.
